OSLER: Effect of PCSK9 Inhibitor Evolocumab on CV Outcomes │ ACC.15 Presentation Slides

Date: March 15, 2015

Keywords: ACC Annual Scientific Session, Angina, Unstable, Antibodies, Monoclonal, Cholesterol, Follow-Up Studies, Hospitalization, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Proprotein Convertases, Subtilisins, Risk, Stroke